Consultation "Bone health in cancer"

Cancer and its treatments can lead to an increase in bone remodeling, increasing the risk of developing osteoporosis. Endocrine therapies for breast and prostate cancer in particular have an adverse effect on bone, but patients with other solid tumors or hematologic diseases often have a significantly increased osteologic risk profile as well. At the same time, long-term antiresorptive therapy, as used to treat bone metastases or osteoporosis, increases the risk for side effects such as osteonecrosis of the jaw or atypical fractures.

The National Center for Tumor Diseases Dresden (NCT/UCC), in collaboration with the Department of Endocrinology of the Medical Clinic 3, offers appropriate counseling as part of the consultation "Bone Health in Cancer" for those affected.

The consultation includes taking a risk history, which is supplemented by laboratory diagnostics and bone densitometry, in order to assess the individual risk of affected patients and to be able to make a therapy recommendation or, if necessary, to initiate an osteoprotective therapy.

Patients with borderline or complex findings, as well as a high osteological risk, particularly benefit from this special offer.